AEON Biopharma, Inc. (AEON)
2025-06-30 | ||||
|---|---|---|---|---|
| Selling, general and administrative | 3,258 | |||
| Research and development | 1,064 | |||
| Change in fair value of contingent consideration | 16 | |||
| Total operating costs and expenses | 4,338 | |||
| (loss) income from operations | -4,338 | |||
| Other income, net | 92 | |||
| Change in fair value of warrants | 542 | |||
| Change in fair value of convertible notes | -1,854 | |||
| Total other (loss) income, net | -2,304 | |||
| (loss) income before taxes | -6,642 | |||
| Net (loss) income | -6,642 | |||
| Earnings per share, basic | -0.6 | |||
| Earnings per share, diluted | -0.6 | |||
| Weighted average number of shares outstanding, basic | 11,090,809 | |||
| Weighted average number of shares outstanding, diluted | 11,090,809 | |||